McKesson Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

McKesson wird ein jährliches Gewinn- und Umsatzwachstum von 15% bzw. 8.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 568.1% betragen.

Wichtige Informationen

15.0%

Wachstumsrate der Gewinne

19.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.8%
Wachstumsrate der Einnahmen	8.1%
Zukünftige Eigenkapitalrendite	568.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M

Feb 01

McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price

Jan 12

5 Reasons Why I Am Considering Adding McKesson To My Portfolio

Dec 27

McKesson Corporation: Still Trading Below Intrinsic Value

Dec 13

Gewinn- und Umsatzwachstumsprognosen

NYSE:MCK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	418,942	4,295	5,758	6,512	11
3/31/2026	391,883	3,952	5,006	6,064	15
3/31/2025	359,959	3,097	5,051	5,857	13
9/30/2024	330,187	2,536	4,313	5,121	N/A
6/30/2024	313,751	2,959	3,256	3,986	N/A
3/31/2024	308,951	3,002	3,627	4,314	N/A
12/31/2023	301,506	2,998	2,892	3,492	N/A
9/30/2023	291,098	3,487	4,306	4,906	N/A
6/30/2023	284,040	3,755	4,466	5,048	N/A
3/31/2023	276,711	3,563	4,601	5,159	N/A
12/31/2022	273,903	3,146	4,190	4,721	N/A
9/30/2022	272,027	2,061	3,952	4,430	N/A
6/30/2022	268,446	1,396	4,639	5,115	N/A
3/31/2022	263,966	1,119	3,899	4,434	N/A
12/31/2021	257,006	1,415	4,323	4,917	N/A
9/30/2021	250,991	-4,804	4,098	4,753	N/A
6/30/2021	245,223	-4,494	3,299	3,982	N/A
3/31/2021	238,228	-4,538	3,901	4,542	N/A
12/31/2020	237,621	-4,189	5,231	5,826	N/A
9/30/2020	234,194	2,228	3,905	4,492	N/A
6/30/2020	231,002	922	2,851	3,363	N/A
3/31/2020	231,051	906	3,868	4,374	N/A
12/31/2019	224,945	-905	3,125	3,615	N/A
9/30/2019	221,981	-626	3,066	3,559	N/A
6/30/2019	217,440	601	4,523	5,046	N/A
3/31/2019	214,319	33	3,479	4,036	N/A
12/31/2018	213,518	-319	2,572	3,165	N/A
9/30/2018	210,927	113	2,751	3,324	N/A
6/30/2018	209,913	-384	N/A	2,543	N/A
3/31/2018	208,357	62	N/A	4,345	N/A
12/31/2017	205,442	4,805	N/A	2,756	N/A
9/30/2017	201,955	4,539	N/A	3,155	N/A
6/30/2017	199,851	4,846	N/A	3,626	N/A
3/31/2017	198,533	5,194	N/A	4,744	N/A
12/31/2016	196,498	2,051	N/A	6,415	N/A
9/30/2016	194,267	2,044	N/A	5,349	N/A
6/30/2016	193,071	2,359	N/A	5,077	N/A
3/31/2016	190,884	2,290	N/A	3,672	N/A
12/31/2015	189,131	2,237	N/A	2,449	N/A
9/30/2015	187,716	2,090	N/A	4,198	N/A
6/30/2015	183,115	1,950	N/A	3,384	N/A
3/31/2015	179,045	1,775	N/A	3,112	N/A
12/31/2014	171,952	1,780	N/A	3,893	N/A
9/30/2014	159,804	1,462	N/A	2,488	N/A
6/30/2014	148,629	1,402	N/A	2,602	N/A
3/31/2014	137,392	1,419	N/A	3,136	N/A
12/31/2013	130,076	1,278	N/A	2,679	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MCKDas prognostizierte Gewinnwachstum (15% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: MCKDie Erträge des Unternehmens (15% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: MCKDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: MCKDie Einnahmen des Unternehmens (8.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: MCKDie Einnahmen des Unternehmens (8.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MCKDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (568.1%).

McKesson Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 7.7% to US$629

Recent updates

McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 7.7% to US$629

McKesson, Oracle, Thoma Bravo Reportedly Among Finalists to Acquire Veradigm

McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter dividend of US$0.71 announced

McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2025

McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff

McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies

McKesson Corporation to Report Q2, 2025 Results on Nov 06, 2024

McKesson: The Correction Is Not Over

CEO & Director notifies of intention to sell stock

Upcoming dividend of US$0.71 per share

McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

CEO & Director notifies of intention to sell stock

Fourth quarter dividend increased to US$0.71

McKesson Corporation Declares Regular Dividend on Common Stock, Payable on October 1, 2024

CEO & Director notifies of intention to sell stock

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

McKesson Corporation to Report Q1, 2025 Results on Aug 07, 2024

McKesson Corporation, Annual General Meeting, Jul 31, 2024

Mckesson Corporation Elects Deborah Dunsire as New Director

Upcoming dividend of US$0.62 per share

Executive VP & CFO notifies of intention to sell stock

With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For

Full year 2024 earnings: EPS exceeds analyst expectations

Third quarter dividend of US$0.62 announced

McKesson Corporation Declares Quarterly Dividend, Payable on June 3, 2024

McKesson Corporation to Report Q4, 2024 Results on May 07, 2024

CEO & Director notifies of intention to sell stock

Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?

Upcoming dividend of US$0.62 per share

McKesson: GLP-1 Contributed More Than 1/3 Of Growth

McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter dividend of US$0.62 announced

High number of new directors

Mckesson Corporation Declares Quarterly Dividend, Payable on April 1, 2024

Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking

McKesson: Why The Company Is Too Richly Valued

McKesson Corporation Reportedly Seeks Buyers for Canada's Rexall Pharmacy

McKesson Corporation (NYSE:MCK) acquired Compile, Inc.

Mckesson Corporation Elects Kevin Ozan as New Director

CEO & Director notifies of intention to sell stock

McKesson Corporation to Report Q3, 2024 Results on Feb 07, 2024

McKesson Appoints Crystal Lennartz to Health Mart and Health Mart Atlas

Upcoming dividend of US$0.62 per share at 0.5% yield

If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity

CEO & Director notifies of intention to sell stock

McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

McKesson Corporation Announces Management Changes

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?

McKesson Corporation Declares Quarterly Dividend, Payable on January 2, 2024

CEO & Director notifies of intention to sell stock

McKesson Corporation to Report Q2, 2024 Results on Nov 01, 2023

McKesson: Still Trading For A Huge Discount

Upcoming dividend of US$0.62 per share at 0.6% yield

Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?

McKesson Corporation Raises Quarterly Dividend, Payable on October 2, 2023

CEO & Director notifies of intention to sell stock

McKesson Corporation to Report Q1, 2024 Results on Aug 02, 2023

McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation

McKesson Unveils New Private Brand of Over-the-Counter Pharmacy Products

CEO & Director notifies of intention to sell stock

McKesson Corporation, Annual General Meeting, Jul 21, 2023